rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BMRN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms
      Nov 16Yahoo FinanceBMRN
      BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline
      Nov 12Yahoo FinanceBMRN
      BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions (NASDAQ:BMRN)
      Nov 4Seeking AlphaBMRN
      H.C. Wainwright reiterates BioMarin stock rating at Neutral
      Nov 4Investing.comBMRN
      BioMarin Pharmaceutical Inc (BMRN) Q3 2026 Earnings Call Highlights: First $1 Billion Revenue ...
      Nov 4Yahoo FinanceBMRN
      BioMarin Likely Able to Support New Prospects, Wedbush Says
      Nov 3Yahoo FinanceBMRN
      Cantor Fitzgerald reiterates Overweight on BioMarin stock at $86
      Nov 3Investing.comBMRN
      BioMarin Pharmaceutical Inc. Q3 2026 Earnings Call Summary
      Nov 3Yahoo FinanceBMRN
      Oppenheimer lowers BioMarin stock price target to $94 on guidance cut
      Nov 3Investing.comBMRN
      BioMarin Beats Q3 Revenue Forecasts but Cuts 2026 Outlook on Voxzogo Timing and Deal Costs
      Nov 3Yahoo FinanceBMRN
      Stifel cuts BioMarin stock price target to $66 on growth concerns
      Nov 3Investing.comBMRN
      BioMarin reports Q3 revenue beat but cuts full-year outlook
      Nov 3Investing.comBMRN
      BioMarin Pharmaceutical Q3 Earnings Call Highlights
      Nov 3Yahoo FinanceBMRN
      BioMarin Pharmaceutical (BMRN) Could Be 21% Undervalued On Mixed Q3 Guidance Cut

      BioMarin Pharmaceutical (BMRN) is back in focus after a mixed Q3 2026 update, with adjusted profit topping analyst expectations while sales came in slightly below forecasts and full year guidance moved lower. Recent trading tells a mixed story for BioMarin Pharmaceutical. The share price slipped 1.83% on the day to US$57.44 yet still shows a 3.03% gain over the past week, while a 90 day share price return down 5.40% contrasts with a 1 year total shareholder return of 8.69%. This suggests...

      Nov 3Yahoo FinanceBMRN
      BioMarin (BMRN) Stock May Be A Bargain After Fabry Therapy Deal
      Nov 3Yahoo FinanceBMRN
      BioMarin Q3 2026 slides: first $1B quarter, guidance cut on timing
      Nov 3Investing.comBMRN
      Earnings call transcript: BioMarin tops Q3 2026 estimates, but shares fall
      Nov 3Investing.comBMRN
      BioMarin: Q3 Earnings Snapshot
      Nov 2Yahoo FinanceBMRN
      Biomarin Pharmaceutical Q3 2026 Earnings Call Transcript
      Nov 2BenzingaBMRN
      BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
      Nov 2Yahoo FinanceBMRN
      BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates
      Nov 2Yahoo FinanceBMRN
      Biomarin Pharma earnings beat by $0.11, revenue topped estimates
      Nov 2Investing.comBMRN
      BioMarin Pharmaceutical (NASDAQ:BMRN) reports Q3 2026 in line with expectations but full-year sales guidance misses expectations
      Nov 2Yahoo FinanceBMRN
      BioMarin Pharmaceutical Q3 Non-GAAP Earnings, Revenue Rise; 2026 Guidance Lowered
      Nov 2Yahoo FinanceBMRN
      BioMarin shares fall despite third quarter beat
      Nov 2Investing.comBMRN
      Biomarin earnings on deck: Amicus integration in focus
      Nov 2Investing.comBMRN
      BioMarin Pharmaceutical (BMRN) Q3 earnings: what to expect
      Nov 1Yahoo FinanceBMRN
      Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking
      Oct 31Yahoo FinanceBMRNTEVA
      BioMarin Signs License Deal for Fabry Disease Therapy Candidate
      Oct 29Yahoo FinanceBMRN
      BioMarin licenses Fabry disease therapy for $70M upfront
      Oct 29Investing.comBMRN
      Baird reiterates Neutral rating on BioMarin stock at $65
      Oct 27Investing.comBMRN
      Analysts’ Opinions Are Mixed on These Healthcare Stocks: BioMarin Pharmaceutical (BMRN), Eli Lilly & Co (LLY) and Bristol-Myers Squibb (BMY)

      Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

      Oct 21The Globe and MailBMRN
      UBS Adjusts BioMarin Pharmaceutical Price Target to $88 From $114, Maintains Buy Rating
      Oct 15Yahoo FinanceBMRN
      1cBio Received Shareholder Proceeds Upon Closing of BioMarin Pharmaceutical Inc.'s Acquisition of Alesta Therapeutics
      Oct 14Yahoo FinanceBMRN
      Raymond James upgrades BioMarin stock to strong buy on valuation
      Oct 12Investing.comBMRN
      Why is BioMarin Pharmaceutical stock gaining today?
      Oct 12Investing.comBMRN
      Bank of America Securities Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

      Tipranks Press Release.

      Oct 10The Globe and MailBMRN
      RBC Capital Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)

      Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailBMRN
      BioMarin to present data on achondroplasia treatment at ASBMR
      Oct 9Investing.comBMRN
      BioMarin Pharmaceutical (BMRN), What Is Behind The Latest Attention?

      BioMarin Pharmaceutical (BMRN) just put fresh clinical data in front of investors, highlighting five year outcomes for POMBILITI plus OPFOLDA in late onset Pompe disease and early stage results for its nivudirsen program. BioMarin Pharmaceutical’s clinical updates arrive after a challenging spell for the stock, with the 30 day share price return down 17.03% and the 7 day move also weaker, while the 1 year total shareholder return remains close to flat at 0.93%. Scan BioMarin Pharmaceutical’s...

      Oct 8Yahoo FinanceBMRN
      Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT) and BioMarin Pharmaceutical (BMRN)

      Detailed price information for Rocket Pharmaceuticals Inc (RCKT-Q) from The Globe and Mail including charting and trades.

      Oct 8The Globe and MailBMRN
      BioMarin Expects Pre-tax Charges Related to Alesta Acquisition to Impact Q3 Adjusted EPS
      Oct 6Yahoo FinanceBMRN
      BioMarin names Cara Bauer as chief people officer
      Oct 6Investing.comBMRN
      BioMarin presents five-year data on Pompe disease treatment
      Oct 2Investing.comBMRN
      BioMarin reports five-year Pompe disease data showing durable motor function

      BioMarin shared five-year data showing a combination therapy helped adults with late-onset Pompe disease maintain motor function.

      Oct 2CNBCBMRN
      BioMarin Says 5-Year Data Shows Durable Efficacy of Pombiliti Plus Opfolda in Pompe Disease
      Oct 2Yahoo FinanceBMRN
      BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress
      Oct 2Yahoo FinanceBMRN
      The Strategic Financial Case for BioMarin Pharmaceutical (BMRN)
      Oct 1Yahoo FinanceBMRN
      BioMarin and Profluent partner on AI-designed enzyme therapies

      Under the agreement, Profluent will deploy its proprietary suite of protein language models to generate new potential drug candidates.

      Oct 1Yahoo FinanceBMRN
      BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN)

      BioMarin Pharmaceutical Inc. stock outlook: Q4 2026–2027 catalysts, DMD BMN 351 data, Voxzogo approval potential, and raised guidance. Click for this BMRN update.

      Sep 21Seeking AlphaBMRN

      This is the newest page. Registered accounts read further back.